Elicera Therapeutics' abstract on the iTANK platform's potential to enhance CAR T-cell treatment of solid tumors accepted for presentation at ISCT 2024

Gothenburg, February 16, 2024 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology platform iTANK, announces today that the company has been invited to present at the scientific conference International Society for Cell & Gene Therapy (ISCT) Meeting 2024 in Vancouver, Canada, May 28 to June 1.

Margareth Jorvid, board member of Elicera Therapeutics, will participate in a networking session to present the company's scientific abstract entitled "The iTANK platform has potential to improve CAR-T cell treatment of solid tumors".

ISCT brings together leading researchers, clinicians and industry experts in cell and gene therapy from around the world. The main purpose of the conference is to promote the exchange of new scientific advances, technological advances and clinical insights in the rapidly developing field of cell and gene therapy. For more information: www.isctglobal.org/isct2024.